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Abstract: Insulin resistance, hyperglycemia, hyperinsulinemia, hyperlipidemia and oxidative 
stress are risk factors related to cardiovascular diseases including congestive heart failure, 
myocardial infarction, ventricular hypertrophy, endothelial nitric oxide impairment in systemic 
blood vessels and the heart, atherosclerosis, and hypercoagulability of blood. The traditional 
focus on insulin sensitivity and blood levels of markers of risk determined in the fasted state is 
inconsistent with the large volume of recent data that indicates that the metabolic defect in the 
pre-diabetic and diabetic condition relates more strongly to postprandial deﬁ  ciency than to the 
fasting state. Risk factors for adverse cardiovascular events can be detected in the pre-diabetic 
insulin-resistant subject based upon the metabolic response to a test meal even in the absence 
of altered fasting parameters. The normal response to a mixed meal includes a doubling of 
insulin action secondary to insulin-induced release of a putative hepatic insulin sensitizing 
substance (HISS) that acts selectively on skeletal muscle. HISS is released only in the fed 
state and accounts for meal-induced insulin sensitization. Blockade of HISS release leads to a 
condition referred to as HISS-dependent insulin resistance, which is suggested as the primary 
postprandial metabolic defect, accounting for postprandial hyperglycemia, hyperinsulinemia, 
hyperlipidemia, and increased oxidative stress in the pre-diabetic and diabetic condition. HISS-
dependent insulin resistance represents a novel hypothesis and suggests a new diagnostic and 
therapeutic target.
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Early diagnosis of diabetes was done by the diagnostician tasting the copious volumes 
of urine produced by their patients. This diagnostic approach led to a severe underes-
timation of the incidence of diabetes. Modern diagnosticians depend almost entirely 
upon determinations of fasting plasma levels of glucose and, less frequently, insulin. 
This approach also leads to a severe underestimation of the metabolic dysfunction that 
is typical of the type 2 diabetic. A state of insulin resistance is recognized to occur 
well prior to the development of diabetes. The pre-diabetic state of insulin resistance 
can be diagnosed by determining the response to a test meal. The theme of this brief 
review is that the metabolic dysfunction in the pre-diabetic state is quantiﬁ  able and 
represents a major risk factor for the development of cardiovascular disease. Post-
prandial hyperglycemia, hyperinsulinemia, hyperlipidemia, and oxidative stress are 
individually and collectively recognizable risk factors. An abnormal meal-induced 
insulin sensitization (AMIS) is proposed as a novel hypothesis to account for the 
pre-diabetic state of insulin resistance which, if uncorrected, progresses to diabetes 
when the pancreatic insulin release is no longer able to compensate for AMIS. In 
this review, I suggest that the “HISS story” may explain the mechanism of AMIS Therapeutics and Clinical Risk Management 2007:3(5) 762
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and affords new approaches to diagnosis and treatment of 
pre-diabetic and diabetic insulin resistance.
Postprandial hyperglycemia
In 1997 the American Diabetes Association (ADA) intro-
duced the term “impaired fasting glucose” to describe 
individuals whose fasting plasma glucose concentration was 
between 110 to 125 mg/dl (ADA 1997). Since this diagnostic 
category was proposed, questions have been raised as to its 
clinical utility and it has been suggested that impaired glucose 
tolerance is a better predictor of both type 2 diabetes and car-
diovascular disease (DECODE Study Group 2001, 2003). In 
an effort to respond to these concerns, the ADA has recently 
proposed that the glucose level used to identify individuals 
with impaired fasting glucose be lowered from 110 to 100 
mg/dl (ADA 2003). Recent studies to evaluate the modiﬁ  ed 
standard have indicated a 4-fold increase in individuals con-
sidered to have impaired fasting glucose following the new 
criteria. Serious questions related to the clinical and public 
health implications of this new impaired fasting glucose 
deﬁ  nition have been raised (Ford et al 2005).
The current approach of screening for type 2 diabetes using 
the fasted metabolic status, while convenient, is not effective. 
In a recent review evaluating the status of screening for type 2 
diabetes, Engelgau et al (2000) stated that one of the criteria for 
appropriate screening is that the tests should detect the preclinical 
stage of disease and that the tests be shown to be acceptable and 
reliable. The conclusion that current screening recommendations 
are not consistent with available evidence was brieﬂ  y reviewed. 
Evidence is accumulating that most people with a 54–67% range 
of impaired glucose tolerance have fasting glucose in the normal 
range. Meta-analysis of 20 different European studies showed 
as many as 31% of those who were diabetic according to post-
challenge plasma glucose had normal fasting values and therefore 
would not have been detected by a screening procedure based 
upon fasting glucose measurements alone.
The majority of studies and diagnosis continue to focus on 
the fasted state. However, the importance of postprandial rather 
than fasting metabolic defects, as related to cardiovascular 
disease, is becoming increasingly recognized. The relationship 
between HbA1c and plasma glucose in patients with type 2 
diabetes was determined at four time points during the day 
and HbA1c levels were found to be signiﬁ  cantly predicted 
by plasma glucose levels measured only at post-lunch and 
extended post-lunch (5 hours) time points (Avignon et al 
1997). The strongest age- and sex-adjusted relative risk for 
all-cause and cardiovascular mortality were associated with 
2 hour post-load plasma glucose levels (de Vegt et al 1999). 
Increased mortality risk has been associated with 2 hour 
post-load plasma glucose levels to a much greater extent than 
with fasting plasma glucose (Hanefeld et al 1996; DECODE 
Study Group 1999). Isolated post-load hyperglycemia is a 
strong predictor of mortality (Simon et al 1987; DECODE 
Study Group 1999; Shaw et al 1999; Vaccaro et al 1999; 
Engelgau et al 2000; Simon and Brandenberger 2002).
It has been suggested that hyperglycemia-induced over-
production of superoxide by the mitochondrial electron trans-
port chain accounts for the four main molecular mechanisms 
implicated in glucose-mediated vascular damage associated 
with blindness, renal failure, nerve damage, atherosclerosis, 
stroke, and hindlimb amputation (Brownlee 2001). Postpran-
dial plasma glucose is an important determinant of both onset 
and development of nephropathy in type 2 diabetic patients 
(Schchiri et al 2000). Low density lipoprotein oxidation 
increases after meals (Diwadkar et al 1999) and directly relates 
to the degree of hyperglycemia (Ceriello et al 1999). Acute 
hyperglycemia is associated with an acute increase in clot-
ting factor VII (Ceriello et al 1988) and enhanced thrombin 
activity that was proportional to the level of hyperglycemia 
(Ceriello et al 1996). The synthesis of ﬁ  brinogen, which is a 
strong risk factor for cardiovascular disease in both diabetic 
and non-diabetic subjects, increases during food intake in 
diabetic patients (Ceriello 1997; Bruttomesso et al 2001).
Acute hyperglycemia also stimulates increased expression 
of proadhesive proteins including ICAM-1 (Ceriello 2003). 
Dunn and Grant (2005) reviewed the relationship between the 
hypercoagulable prothrombic state that occurs in type 2 diabe-
tes and cardiovascular disease risk. Hypertriglyceridemia and 
hyperglycemia have been shown to have an independent and 
cumulative effect on postprandial production of nitrotyrosine 
and adhesion molecules (Ceriello et al 2004).
In a review of the importance of postprandial hypergly-
cemia on the development of cardiovascular disease, Haffner 
(1998) suggested that atherosclerotic changes start to develop 
in the pre-diabetic state when postprandial blood glucose 
levels are only moderately elevated above normal levels. 
He suggested, however, that increased insulin resistance and 
hyperinsulinemia may be responsible for the atherosclerotic 
changes and that hyperglycemia may be a marker but not a 
cause of these changes.
Postprandial lipidemia
The hypothesis that atherogenesis is a postprandial phenomenon 
(Zilversmit 1979) was largely ignored until fairly recently when 
re-emphasis on the acute response to test meals demonstrated 
a clear superiority in predicting cardiovascular risk factors. An Therapeutics and Clinical Risk Management 2007:3(5) 763
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oral glucose tolerance test resulted in hyperglycemia and similar 
cardiovascular responses in both healthy and diabetic subjects. 
However, the use of the more physiological mixed meal test 
revealed myocardial endothelial dysfunction in the diabetic sub-
jects. Myocardial blood ﬂ  ow, which was similar in fasted dia-
betic and healthy subjects, increased signiﬁ  cantly in response to 
a standardized mixed meal in the control subjects but decreased 
signiﬁ  cantly in the diabetic patients (Scognamiglio et al 2005). 
The superiority of a mixed meal versus the oral glucose toler-
ance test, related to cardiac dysfunction, was proposed to relate 
to the postprandial hypertriglyceridemia which only occurred 
using the test meal (Scognamiglio et al 2005). A negative 
inﬂ  uence of postprandial hypertriglyceridemia on endothelial 
function has been reported in diabetic subjects (Bae et al 2001; 
Anderson et al 2001). Postprandial hypertriglyceridemia is a 
recognized independent predictor of cardiovascular pathology 
(Anderson et al 2001).
Postprandial dyslipidemia is prevalent in diabetic patients 
even with normal fasting triglyceride concentrations (Mero 
et al 1998). Insulin resistance causes increased ﬂ  ux of free 
fatty acids and thus enhanced VLDL synthesis in the liver. 
Postprandial hypertriglyceridemia contributes to the meta-
bolic disturbances transforming lipoprotein subclasses into 
more atherogenic forms.
Healthy, male, ﬁ  rst-degree relatives of patients with type 
2 diabetes have insulin resistance and postprandial hypertri-
glyceridemia despite having normal fasting triglyceride levels 
(Axelsen et al 1999). Newly diagnosed hypertensive patients with 
hypertriglyceridemia were more insulin resistant and showed 
greater postprandial hypertriglyceridemia than hypertensive 
patients not showing elevated fasting levels of triglycerides 
(Hwu et al 2002). Atherosclerosis is an inﬂ  ammatory disorder 
involving leukocytes. The postprandial triglyceride increment 
after a fat meal was paralleled by a leukocyte increment due 
to an increase in neutrophils in the ﬁ  rst two postprandial hours 
(van Oostrom et al 2003). It has even been suggested that the 
cardiovascular risk recognized to occur with chronic smokers 
is related to insulin resistance and postprandial dyslipidemia 
that is not mirrored by fasting hypertriglyceridemia (Eliasson et 
al 1997). The recognized impact of various nutritional supple-
ments or beverages, including tea, in lowering the incidence of 
cardiovascular disease may be related to the demonstration of 
attenuation of the postprandial increase in plasma triglyceride 
levels following a fat load (Unno et al 2005).
Postprandial hyperinsulinemia
Impaired glucose metabolism was demonstrated to be a pre-
dictor of development of congestive heart failure in a large 
community-based sample of elderly men (Ingelsson et al 
2005). Surprisingly, when insulin sensitivity and the impaired 
glucose tolerance were analyzed as co-variates, obesity was 
no longer a signiﬁ  cant predictor of the subsequent develop-
ment of congestive heart failure. This suggests that obesity 
may be a coincidental predictor of congestive heart failure 
and may simply be a marker of insulin resistance, which is 
compensated for by hyperinsulinemia.
Ingelsson et al (2005) suggest that the hyperinsulinemia 
associated with impaired glucose metabolism represents a 
risk factor through several possible mechanisms. Insulin acts 
as a growth factor in the myocardium as shown by increased 
myocardial mass and decreased cardiac output in rats exposed 
to sustained hyperinsulinemia (Holmang et al 1996). Hyper-
insulinemia leads to sodium retention (DeFronzo et al 1975) 
which may exacerbate subclinical myocardial dysfunction 
due to blood volume expansion. Hyperinsulinemia leads to 
sympathetic nervous system activation (Anderson et al 1991) 
which is a presumed causal factor for congestive heart failure 
(Kannel and Belanger 1991; Bell 2003). Insulin resistance is 
related to increased effectiveness of angiotensin II on blood 
pressure (Gaboury et al 1994) and cellular hypertrophy and 
collagen production (Sartori et al 2004) in individuals with 
hypertension, leading to myocardial hypertrophy and ﬁ  brosis 
(Bell 2003) and likely subsequent congestive heart failure.
The relationship between elevated insulin levels and 
heart disease remains controversial mainly because it is 
often not clear exactly what is being measured by insulin 
assays. Using an assay speciﬁ  c for insulin and proinsulin, 
Zethelius et al (2005) suggested that proinsulin levels rather 
than insulin levels were a better predictor of development of 
coronary heart disease in a study of older Swedish males. The 
literature supporting proinsulin levels as a better marker than 
insulin suggests a unique biological role for proinsulin and 
could also be interpreted to indicate that the fasting levels of 
proinsulin are not representative of postprandial responses, 
rather that the slow metabolic degradation of proinsulin may 
lead to greater fasting levels of proinsulin and thus reﬂ  ect 
postprandial hyperinsulinemia.
Somogyi et al (2005) studied hyperglycemia-induced 
oxidative stress using the rat streptozotocin model. The dia-
betic rats not treated with insulin showed enhanced activity 
of antioxidant enzymes. Diabetic rats treated with insulin 
showed decreased total oxidant scavenger capacity and 
development of left ventricular hypertrophy. They suggested 
that increased activity of the antioxidant enzymes inhibits 
subcellular remodeling processes thereby inhibiting cardiac 
hypertrophy, whereas insulin decreases the activity of the Therapeutics and Clinical Risk Management 2007:3(5) 764
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antioxidant system and can enhance the function of other 
localized tissue-speciﬁ  c growth factors. Chronic hyperinsu-
linemia may contribute to pathologies related to unregulated 
growth stimulation.
Postprandial oxidative stress
Ceriello (2000) has suggested that increased postprandial 
oxidative stress may be the common pathway through which 
the majority of diabetic complications occur. As previously 
discussed, both hyperglycemia and hyperlipidemia lead to 
increased oxidative stress. Meal consumption in healthy 
subjects has been shown to acutely reduce antioxidant 
defenses (Ceriello et al 1998) and produces an oxidative 
stress (Ceriello et al 1998; Ursini et al 1998). Oxidative 
stress is linked to the pathogenesis of cardiovascular dis-
ease (Griendling and Alexander 1997) and hypertension 
(Nakazono et al 1991). Antioxidants produce vasodilation 
in patients with hypertension and coronary artery disease 
(Ceriello et al 1991; Levine et al 1996; Solzbach et al 1997). 
This is consistent with evidence that free radical produc-
tion accompanies endothelial dysfunction (Griendling and 
Alexander 1997) and that antioxidants improve endothelial 
dysfunction (Anderson et al 1995). Ceriello, recognizing the 
strong relationship between processing a meal and the pro-
duction of oxidative stress, concluded that “…paradoxically, 
the vast majority of the studies on cardiovascular disease risk 
factors have been conducted by measuring them in strictly 
fasting conditions. This simply means that most of the data 
available to date may not reﬂ  ect the real situation” (Ceriello 
2000, p128).
It has been suggested that nitric oxide is inactivated by 
excess superoxide production in the postprandial state in 
both healthy and diabetic subjects and that the subsequent 
impaired vascular reactivity can be predicted based upon the 
circulating level of nitrotyrosine (Ceriello 2002). Vitamin E 
and other antioxidants administered to diabetics increase 
tissue antioxidant levels, improve the action of insulin, 
promote endothelial function, prevent oxidation of serum 
lipids, suppress protein glycation and reduce the oxidative 
load (Rosen et al 1995). Drugs that have signiﬁ  cant antioxi-
dant activity may improve the risk factors for cardiovascular 
disease through the sequestration of superoxide, thereby 
reducing the nitric oxide-dependent cardiovascular and 
metabolic dysfunctions.
Whiteside (2005) reviewed the literature on vascular 
complications of diabetes and reactive oxygen species, 
concluding that attention must be directed to more effective 
antioxidants as few clinical trials indicate a major therapeutic 
beneﬁ  t from current monotherapy approaches. A recent study 
of ours strongly supports this conclusion. Insulin resistance 
produced in response to the chemical hepatotoxin, thioacet-
amide, can be prevented from developing by the use of an 
antioxidant cocktail consisting of vitamin E, vitamin C, and 
S-adenosylmethionine, but not the individual components of 
the cocktail (Ming et al 2006). The insulin resistance produced 
by thioacetamide was shown to be represented by HISS-
dependent insulin resistance with direct (HISS-independent) 
insulin action remaining unaltered (HISS and HISS-dependent 
insulin resistance are discussed later). The use of an antioxi-
dant cocktail designed to protect multiple sites may offer a 
more rational approach to antioxidant therapy.
Cardiovascular disease
Insulin resistance in type 2 diabetics is associated with 
increased prevalence of coronary heart disease, blood coagu-
lability, and dislipidemia leading to the suggestion that reduc-
ing insulin resistance in diabetics may reduce their tendency 
to develop thrombosis and hence coronary heart disease risk 
(Wannamethee et al 2004). In post-myocardial infarction 
patients, the metabolic syndrome and diabetes were prevalent 
and associated with increased risk of cardiovascular events 
and death (Levantesi et al 2005). Impaired glucose regula-
tion has been related to left ventricular systolic (Arnlov et al 
2001) and diastolic (Arnlov et al 2005) dysfunction and left 
ventricular remodeling (Devereux et al 2000; Sundstrom et al 
2000; Rutter et al 2003). The exaggerated cardiac damage 
in response to acute ischemia/reperfusion injury induced by 
repetitive hyperglycemia was prevented by co-administration 
of acarbose (Frantz et al 2005).
Chronic inflammatory diseases such as rheumatoid 
arthritis (Dessein et al 2005), polycystic ovarian syndrome 
(Dokras et al 2005; Kravariti et al 2005), and obesity (Karelis 
et al 2005) represent a high risk factor for development of 
insulin resistance. Primary renal disease is associated with 
postprandial hypertriglyceridemia (Charlesworth et al 2005). 
C reactive protein has recently been demonstrated to be asso-
ciated with high incidence of insulin resistance (Festa et al 
2000; Lee et al 2004; Rutter et al 2004) and cardiovascular 
disease (Koenig et al 2004; Pai et al 2004) and is also elevated 
in the above chronic inﬂ  ammatory disease conditions. Low 
grade systemic inﬂ  ammation, identiﬁ  ed by elevated C reac-
tive protein, is present in normal weight subjects who show 
insulin resistance but no other metabolic abnormalities 
(Bo et al 2005). Testing for high sensitivity C reactive protein 
has recently (Pearson et al 2003) been recommended by the 
American Heart Association for the assessment of the risk Therapeutics and Clinical Risk Management 2007:3(5) 765
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for developing cardiovascular disease (Rifai 2005). Although 
one study suggests that the association between C reactive 
protein and the metabolic syndrome disappears after adjust-
ment for ﬁ  tness level (Lamonte et al 2005).
Postprandial nutrient processing 
and the HISS hypothesis
We have recently demonstrated (Lautt et al 2001) that the 
glucose disposal effect of a bolus of insulin is approximately 
doubled in the early postprandial state and this meal-induced 
insulin sensitization (MIS) progressively decreases to a 
baseline level of insulin sensitivity after 24 hours of fasting. 
As a brief overview, the MIS process is proposed to occur 
as a result of insulin acting on the liver to release a hepatic 
insulin sensitizing substance (HISS) that acts selectively on 
skeletal muscle to stimulate glucose uptake. HISS action thus 
accounts for the large postprandial glucose sequestration in 
skeletal muscle (Xie and Lautt 1996a, 1996b; Moore et al 
2002). The HISS hypothesis further proposes that blockade 
of HISS release results in postprandial hyperglycemia, which 
leads to postprandial compensatory hyperinsulinemia, with 
the increased insulin acting primarily on the liver and adipose 
tissue and resulting in increased formation of triglycerides 
and VLDL as well as increased free radical production (i.e. 
the metabolic syndrome). The sequence of discoveries lead-
ing to the current status of the HISS hypothesis is reviewed 
(Lautt 2004) as are methods to evaluate HISS-dependent and 
HISS-independent insulin action (Lautt 2003).
Methods used to quantitate the MIS process rely on 
an index of insulin sensitivity determined before and after 
administration of a mixed test meal. Although the original 
discovery of the dependence of whole body insulin action 
on hepatic nerves was made in cats using a standard insulin 
tolerance test (Xie et al 1993), the problems associated with 
the hypoglycemia that ensues following a bolus of insulin 
led us to develop the rapid insulin sensitivity test (RIST). 
The RIST is simply a rapidly sampled transient euglycemic 
clamp (Lautt et al 1998) and has been used in cats, mice, rats, 
pigs, and humans and with a wide range of physiological 
and pathophysiological models (for review see Lautt 2003). 
The RIST and the insulin tolerance test are equally able to 
detect HISS action and different insulin effectiveness in the 
fed versus fasted state (Reid et al 2002). The RIST is highly 
reproducible and can be repeated several times consecutively 
in the same animal.
Abnormal insulin delivery, such as produced by a 
single large bolus of 300 mU/kg, results in an inability of 
subsequent normal doses of insulin to cause HISS release. 
This would appear to be protective in nature. Further, when 
insulin is administered as pulses, subsequent insulin action is 
demonstrated to be unaffected whereas administration of 
the same dose of insulin by constant infusion results in 
an impairment of HISS release in subsequent tests with 
the degree of impairment related to the duration of the 
constant infusion (Reid and Lautt 2004). Similar endo-
crine dependence on pulsatile stimulation is seen with the 
gonadotropins, which, when delivered in pulses results in 
testosterone secretion but when delivered in the same dose 
but at a constant rate results in chemical castration (Belchetz 
et al 1978). In our hands, the 3-hour hyperinsulinemic 
euglycemic clamp utilizing continuous insulin infusion was 
not capable of determining differences in insulin sensitivity 
before and after a meal except for an increased response in 
the fed state within the ﬁ  rst 30 minutes of infusion (Reid et 
al 2002). Others (Zsuga et al 2004) however have studied 
aspects related to HISS and have found similar results using 
a prolonged clamp or the RIST. Studies in the conscious 
dog (Moore et al 2002) were able to detect signiﬁ  cant HISS-
like responses using a prolonged clamp. HISS release is 
dependent on hepatic parasympathetic tone. Cardiovascular 
parasympathetic dysfunction is associated with diabetes and 
is detectable at the pre-diabetic stage of insulin resistance 
(Lautt 1999). A 90 minute hyperinsulinemic euglycemic 
clamp resulted in a decrease in cardiac parasympathetic 
tone and an increase in sympathetic nerve activity in skel-
etal muscle (Van de Borne et al 1999) suggesting that the 
prolonged, constant-infusion euglycemic clamp may not 
be the most appropriate index of insulin sensitivity under 
conditions, such as diabetes and obesity, where normal 
parasympathetic tone is important. Use of the euglycemic 
clamp also resulted in elevated levels of cytokines, beta 
amyloid and norepinephrine in cerebrospinal ﬂ  uid (Fishel 
et al 2005). It is crucial that any methods used to study MIS, 
and the postprandial defect we refer to as HISS-dependent 
insulin resistance (HDIR), must be able to quantify insulin 
effect in the fed and fasted state.
HISS release can be acutely blocked by surgical parasym-
pathetic denervation of the liver which results in decreased 
postprandial insulin sensitivity that is indistinguishable from 
that measured in the fasted state. Further, after hepatic dener-
vation, mimicking the hepatic parasympathetic permissive 
signal through intraportal venous infusion of acetylcholine 
does not result in a direct impact on glycemia but the restored 
parasympathetic signal allows insulin to cause HISS release. 
Both the defect in insulin response subsequent to hepatic 
denervation and its restoration subsequent to intraportal Therapeutics and Clinical Risk Management 2007:3(5) 766
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but not intravenous acetylcholine has been demonstrated 
to occur in skeletal muscle (Xie and Lautt 1996a, 1996b; 
Moore et al 2002).
The ability of surgical denervation of the liver to 
result in a selective inhibition of skeletal muscle response 
to glucose could suggest either a neural or hormonal 
link between the liver and skeletal muscle. However, 
the observation that restoration of the parasympathetic 
permissive signal can be achieved by intraportal but not 
intravenous continuous administration of acetylcholine 
proves the hormonal nature of the regulatory process. It 
is important to indicate that the parasympathetic signal in 
the liver is “permissive” in nature as demonstrated by the 
observation that the intraportal acetylcholine infusion does 
not result in an alteration of baseline glycemia but does 
allow insulin to have a restored effect in skeletal muscle. 
Similar studies have been done related to the hepatic 
parasympathetic requirement for sequential activation of 
hepatic muscarinic receptors and nitric oxide production. 
Sadri and Lautt (1999) reported that nitric oxide synthase 
antagonists were much more effective at blocking HISS 
release than were intravenous doses. Similarly, in the 
presence of blockade of hepatic nitric oxide synthase, the 
permissive parasympathetic signal could be restored by 
intraportal but not intravenous administration of nitric 
oxide donors. Guarino et al (2004) demonstrated that the 
sequence of parasympathetic nerve activation involves 
sequential muscarinic and secondary nitric oxide synthase 
activation as demonstrated by the ability of a nitric oxide 
donor to reverse atropine-induced HISS-dependent insulin 
resistance and the inability of intraportal acetylcholine to 
reverse HISS-dependent insulin resistance produced by 
prior blockade of hepatic nitric oxide synthase.
Cats (Xie and Lautt 1995), rats (Lautt et al 2001), and 
dogs (Moore et al 2002) that have been fasted for 16 hours 
continue to show a small HISS-dependent component of 
insulin action of approximately 25%–35%. The HISS-
independent component (direct insulin action) is not altered 
by feeding or fasting nor is it altered by administration of 
atropine or hepatic denervation or blockade of hepatic nitric 
oxide (Lautt et al 2001). The HISS-dependent component of 
insulin action represents approximately 55% of the glucose 
disposal action of boluses of insulin over a wide range of 
insulin doses, from a barely detectable stimulation of glucose 
uptake induced by 5 mU/kg up to 100 mU/kg.
HISS-dependent insulin resistance (HDIR) accounts for 
the insulin resistance seen in a wide range of animal models 
including the spontaneously hypertensive rat, sucrose-fed 
rats, animals with liver disease induced by chronic bile duct 
ligation or chemical toxins, adult offspring of fetal alcohol 
exposure, acute stress and ageing, physical interruption of 
hepatic parasympathetic nerves, and pharmacological block-
ade of hepatic muscarinic cholinergic receptors, nitric oxide 
production or cyclooxygenase (reviewed Lautt 2003).
The permissive feeding signal (Figure 1), delivered to 
the liver through the parasympathetic nerves acts via mus-
carinic receptor activation and generation of hepatic nitric 
oxide which then results in the insulin dose-related release of 
HISS (Sadri and Lautt 1999; Guarino et al 2003). The nitric 
oxide acts through hepatic guanylyl cyclase (Correia et al 
2002; Guarino et al 2004). Hepatic glutathione level, which 
decreases signiﬁ  cantly with fasting and rapidly increases 
following re-feeding is also an essential component of the 
feeding response in rats (Guarino et al 2003; Lautt et al 2005; 
Sadri et al 2006). The mechanism of regulation of hepatic 
glutathione in response to feeding is unknown.
In a recent study we utilized a liquid test meal admin-
istered through a gastric catheter to quantitate MIS in both 
conscious and anesthetized rats by determining insulin sen-
sitivity before and after the meal (Sadri et al 2006). A mixed 
liquid test meal, but not sucrose or glucose, resulted in MIS 
that could be completely reversed by atropine administration 
(Figure 2). The insulin sensitivity index increased in response 
to feeding and was reversed completely back to fasting levels 
of sensitivity by atropine. Similarly, prior denervation of the 
liver completely prevented the MIS process from occurring, 
thereby conﬁ  rming the central role of hepatic parasympa-
thetic nerves in the feeding signal. MIS has also recently been 
shown to occur in healthy male volunteers and blockade of 
MIS has been conﬁ  rmed to occur in humans subsequent to 
atropine administration (Patarrao et al 2005).
Therapeutic potential
The HISS hypothesis is suggested to account for meal-
induced insulin sensitization. Absence of HISS action, or 
HISS-dependent insulin resistance (HDIR), is suggested to 
account for the major postprandial metabolic dysfunctions 
seen in the pre-diabetic insulin resistant state. The conclu-
sions reached in many of the studies referred to previously 
suggest that therapeutic intervention should be focused on 
correction of the postprandial insulin resistance. In a recent 
review evaluating new drug targets for type 2 diabetes and 
the metabolic syndrome, Moller (2001 p821) emphasized that 
current therapies for type 2 diabetes were developed in the 
absence of deﬁ  ned molecular targets or an understanding of 
disease pathogenesis: “These therapies have limited efﬁ  cacy, Therapeutics and Clinical Risk Management 2007:3(5) 767
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limited tolerability, and signiﬁ  cant mechanism-based side 
effects. Of particular concern is the tendency for most treat-
ments to enhance weigh gain. Several current approaches 
are also associated with episodes of hypoglycemia, and few 
of the available therapies adequately address underlying 
defects such as obesity and/or insulin resistance.” He further 
concluded that “Thus, newer approaches are desperately 
needed. Particular emphasis should be placed on ﬁ  nding 
and using mechanisms that are dependent on physiological 
responses and that result in weight loss.” With the recent 
understanding of the physiology and pathology related to 
HISS, targeting of this mechanism offers a novel approach 
to restoring normal postprandial physiological insulin sen-
sitivity in skeletal muscle, the major site where the insulin 
resistance is generally acknowledged to occur in many insulin 
resistant states.
Conclusion
Postprandial hyperglycemia, hyperinsulinemia, hyperlipid-
emia and increased oxidative stress are strongly related to 
cardiovascular disease. Meal-induced insulin sensitization 
(MIS) normally occurs in response to a mixed meal, and 
absence of MIS is based on inability of the liver to secrete 
HISS in response to insulin. The argument has been made that 
HDIR could account for the primary endocrine defect in the 
pre-diabetic and diabetic state. Absence of MIS results in altered 
postprandial nutrient processing away from skeletal muscle 
and toward lipid production by liver and fat cells. These are all 
hypotheses that should be tested in the clinical setting.
The absence of MIS in response to glucose or sucrose 
“meals” in rats has major implications for interpretation of 
a large body of research, based on the oral glucose tolerance 
test, if conﬁ  rmed in humans.
Figure 1 Feeding results in an increase of hepatic glutathione (GSH) and a parasympathetic signal to the liver that acts, via acetylcholine, on muscarinic receptors to 
activate NO release which, in turn, activates adenylyl cyclase. Both of these signals are permissive and both are needed in order that insulin can cause the release of hepatic 
insulin sensitizing substance (HISS). HISS acts selectively on skeletal muscle. Blockade of any portion of these pathways leads to blockade of HISS release and a state of 
HISS-dependent insulin resistance which is physiologically regulated to occur in the fasted state but, when not activated by feeding, is suggested to account for postprandial 
hyperglycemia, hyperinsulinemia, hyperlipidemia, and increased oxidative stress.Therapeutics and Clinical Risk Management 2007:3(5) 768
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Although we advocate the use of the rapid insulin sensi-
tivity test, any method used to evaluate the mechanisms and 
consequence of abnormal meal-induced insulin sensitization 
must clearly demonstrate a difference in insulin effect in the 
fed and fasted state.
HDIR is suggested to occur in association with a wide 
range of chronic inflammatory states and to contribute 
negatively as a strong risk factor for development of dia-
betes, obesity, cardiac and vascular disease, and asthma. If 
the “HISS story” is fundamentally correct, it represents a 
new paradigm impacting diagnosis and therapy of a broad 
spectrum of metabolic disorders.
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